

A Phase 1 Study to Assess the Safety, Tolerability and PK of ARRY-380 - an Oral Inhibitor of HER2

Array BioPharma

1.

✉ **Corresponding author:** Array BioPharma, array.biopharma@cureus.com

Categories: Oncology

Keywords:

How to cite this poster

Biopharma A (2012) A Phase 1 Study to Assess the Safety, Tolerability and PK of ARRY-380 - an Oral Inhibitor of HER2. Cureus 4(9): e83.

Abstract

ARRY-380 is a selective, oral HER2 inhibitor with satisfactory PK, and good predicted target coverage. It is well tolerated with low incidence and severity of diarrhea, rash, fatigue.

Open Access

Published 09/17/2012

Copyright

© Copyright 2012

Biopharma. This is an open access article distributed under the terms of the Creative Commons Attribution License CC-BY 3.0., which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Distributed under

Creative Commons CC-BY 3.0

